Clinical trial · Interventional
Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants
Prospective, Open-Label, Non-Comparative, Multicenter Study for the Secondary Prophylaxis of Invasive Fungal Infections (IFI) With Voriconazole in Patients With Allogeneic Stem Cell Transplants (SCT).
NCT00143312CI-TRIAL-00002688VOSIFIcompletedPhase 4Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To prevent recurrence of invasive fungal infection in patients with allogeneic stem cell transplants
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prophylaxis Of Invasive Fungal Infections | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| voriconazole | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1
- interventionNames
- Drug: voriconazole
Primary outcomes (1)
- measure
- Occurrence of Proven or Probable Invasive Fungal Infection (IFI): Start of Prophylaxis Until 12-month Follow-up Visit
- timeFrame
- 12 months
- description
- Number of participants developing a proven or probable IFI from start of voriconazole prophylaxis until 12-month follow up
Secondary outcomes (6)
- measure
- Occurrence of Proven or Probable Invasive Fungal Infection (IFI): Start of Prophylaxis Until 6-month Follow-up Visit
- timeFrame
- 6 months
- description
- Number of participants developing a proven or probable IFI from start of voriconazole prophylaxis until 6-month follow up
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with proven or probable IFI in previous 12 months receiving an allogenic stem cell transplant for any haematological disease Exclusion Criteria: * Pregnant or lactating women * Severe disease other tham the underlying condition * Active, symptomatic uncontrolled Invasive Fungal Infection * Any evidence of active fungal disease as defined by MSG-EORTC criteria * Concomitant use of Voriconazole 36 hours before chemotherapy until 48 hours after chemotherapy * Other medical conditions, including HIV positive serology that would interfere with the evaluation of therapeutic response or safety of study drug
References
Publications (0)
Data not yet available
No reference posted for this study.